|Bid||1,465.60 x 0|
|Ask||1,466.20 x 0|
|Day's range||1,455.40 - 1,502.00|
|52-week range||1,280.92 - 2,746.59|
|Beta (5Y monthly)||0.29|
|PE ratio (TTM)||13.45|
|Earnings date||01 Feb 2023|
|Forward dividend & yield||0.76 (5.49%)|
|Ex-dividend date||17 Nov 2022|
|1y target est||N/A|
You’d think fund mangers would have deployed degree of scepticism after years of overvalued businesses
It's not very often that a FTSE-100 heavyweight sees its share price rise by as much as 13% in a day - but that happened today to the drugs giant GSK. The share price rise was sparked by a court ruling in Florida that declared there was no reliable evidence that Zantac, once its best-selling drug, causes cancer. Based on the compound ranitidine, which was developed by Glaxo - one of the two companies that created GSK - in 1976, it shot to stardom as a cure for heartburn and ulcers.
The GSK share price is rising strongly following a key legal ruling in the US. Should I consider buying the FTSE 100 stock for my portfolio? The post Why has GSK’s share price soared 8% today? appeared first on The Motley Fool UK.